CN102066362A - 二氢吲哚酮衍生物 - Google Patents

二氢吲哚酮衍生物 Download PDF

Info

Publication number
CN102066362A
CN102066362A CN2009801187648A CN200980118764A CN102066362A CN 102066362 A CN102066362 A CN 102066362A CN 2009801187648 A CN2009801187648 A CN 2009801187648A CN 200980118764 A CN200980118764 A CN 200980118764A CN 102066362 A CN102066362 A CN 102066362A
Authority
CN
China
Prior art keywords
optionally substituted
compound
alkyl
cancer
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2009801187648A
Other languages
English (en)
Other versions
CN102066362B (zh
Inventor
袁哲东
张小敏
王胡博
朱雪焱
徐宏江
付辉
宋伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Pharmaceutical Industry
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Shanghai Institute of Pharmaceutical Industry
Jiangsu Chia Tai Tianqing Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Pharmaceutical Industry, Jiangsu Chia Tai Tianqing Pharmaceutical Co Ltd filed Critical Shanghai Institute of Pharmaceutical Industry
Priority to CN200980118764.8A priority Critical patent/CN102066362B/zh
Publication of CN102066362A publication Critical patent/CN102066362A/zh
Application granted granted Critical
Publication of CN102066362B publication Critical patent/CN102066362B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

公开了能够调节蛋白酪氨酸激酶活性的二氢吲哚酮类化合物、这类化合物的制备方法、以及包含这类化合物的药物组合物，还涉及这类化合物及其药物组合物治疗和/或预防有机体中与蛋白质酪氨酸激酶有关的疾病的用途，特别是治疗和/或预防肿瘤以及与成纤维细胞增殖相关的疾病。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN200980118764.8A 2008-05-23 2009-05-25 二氢吲哚酮衍生物 Expired - Fee Related CN102066362B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200980118764.8A CN102066362B (zh) 2008-05-23 2009-05-25 二氢吲哚酮衍生物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN200810098055.5 2008-05-23
CN200810098055 2008-05-23
CN200980118764.8A CN102066362B (zh) 2008-05-23 2009-05-25 二氢吲哚酮衍生物
PCT/CN2009/071967 WO2009140928A1 (zh) 2008-05-23 2009-05-25 二氢吲哚酮衍生物

Publications (2)

Publication Number Publication Date
CN102066362A true CN102066362A (zh) 2011-05-18
CN102066362B CN102066362B (zh) 2014-07-30

Family

ID=41339793

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980118764.8A Expired - Fee Related CN102066362B (zh) 2008-05-23 2009-05-25 二氢吲哚酮衍生物

Country Status (7)

Country Link
US (1) US8829039B2 (zh)
EP (1) EP2292613B1 (zh)
KR (1) KR101375156B1 (zh)
CN (1) CN102066362B (zh)
CA (1) CA2725001C (zh)
RU (1) RU2468022C2 (zh)
WO (1) WO2009140928A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018721B1 (ru) 2008-08-25 2013-10-30 Айрм Ллк Модуляторы сигнального пути hedgehog
CN104829596B (zh) * 2014-02-10 2017-02-01 石家庄以岭药业股份有限公司 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
CN108368108B (zh) * 2015-11-12 2021-09-21 岭南大学研究合作基金会 包含作为活性成分的7-氮杂吲哚啉-2-酮衍生物或其可药用盐的药物组合物
CN106047338B (zh) * 2016-06-21 2018-10-30 西安交通大学 一种靶向EphrinB2荧光标记分子探针及其制备方法和应用
BR112019006023A2 (pt) * 2016-09-29 2019-06-18 Equinox Sciences Llc forma cristalina, métodos de preparação da forma cristalina e do composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou enfermidade e para modular atividade de cinase.
CN108191835A (zh) * 2018-01-09 2018-06-22 中国药科大学 一类新型的含吡咯环和吲哚啉结构rip1激酶抑制剂及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1255752E (pt) * 2000-02-15 2007-10-17 Pharmacia & Upjohn Co Llc Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
EP1349852A2 (en) * 2000-12-20 2003-10-08 Sugen, Inc. 4-(hetero)aryl substituted indolinones
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
AU2002324684B2 (en) * 2001-08-15 2006-10-05 Pharmacia And Upjohn Company Llc Crystals including a malic acid salt of N-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3H-indole-3-ylidene) methyl]-2, 4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途
US7928136B2 (en) * 2006-09-11 2011-04-19 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
ES2565683T3 (es) * 2006-09-15 2016-04-06 Xcovery, Inc. Compuestos inhibidores de quinasa
CN101328166B (zh) 2008-07-10 2012-07-18 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的2-吲哚满酮衍生物

Also Published As

Publication number Publication date
EP2292613A1 (en) 2011-03-09
CA2725001A1 (en) 2009-11-26
EP2292613A4 (en) 2012-05-09
CA2725001C (en) 2014-05-13
WO2009140928A1 (zh) 2009-11-26
RU2468022C2 (ru) 2012-11-27
EP2292613B1 (en) 2015-09-30
KR101375156B1 (ko) 2014-03-18
KR20110010800A (ko) 2011-02-07
CN102066362B (zh) 2014-07-30
RU2010152560A (ru) 2012-06-27
US8829039B2 (en) 2014-09-09
US20110275671A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
US10793543B2 (en) Selective C-KIT kinase inhibitor
CN104530061B (zh) 埃克替尼盐酸盐晶型、药物组合物和用途
TWI804933B (zh) 用作cdk7激酶抑制劑的化合物及其應用
ES2315711T3 (es) Acidos de heteroaril benzofurano sustituidos.
CN105555782A (zh) 喹唑啉衍生物及其制备方法
WO2010121486A1 (zh) 基于吉西他滨结构的前药及其合成方法及应用
CN102066362A (zh) 二氢吲哚酮衍生物
CN107759600A (zh) 作为jak抑制剂的吡咯并嘧啶化合物的结晶
TWI448461B (zh) 4-aniline-6-butenamide-7-alkyl ether quinazoline derivatives, methods and uses thereof
JP6779318B2 (ja) 抗転移性２Ｈ‐セレノフェノ［３，２‐ｈ］クロメン、それらの合成、および同薬剤の使用方法
WO2018068665A1 (zh) 微管蛋白抑制剂
AU2015303724A1 (en) Quinazoline derivative
CN106946761A (zh) 吲哚甲酰胺类化合物及其应用
CN109111439B (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
JP2015523349A (ja) ポリフィリンｉのアシル化誘導体、その調製方法及び使用
CN107739381A (zh) 莪术醇衍生物及其在制备抗肿瘤药物中的应用
CN106866642A (zh) 含芳基酰腙结构的喹唑啉类化合物及其应用
CN107652275B (zh) 喹唑啉衍生物及其制备方法和用途
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
CN101759665B (zh) 取代苯基哌嗪芳烷醇衍生物及其在制备镇痛药物中的应用
CN104119321B (zh) 二氢吲哚酮衍生物的二马来酸盐及其多晶型物
CN104334571B (zh) 重楼皂苷i的酰化衍生物、及其制备方法和应用
CN102688250A (zh) 偶氮类衍生物做为rsk2抑制剂的合成及应用
CN109369634B (zh) 具有抗肿瘤活性的2-甲氧基烟酰胺衍生物制备方法及用途
CN116120327A (zh) β-榄香烯13,14-位对称的双取代衍生物及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: 200040 Beijing West Road, Shanghai, No. 1320

Applicant after: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY

Applicant after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Address before: 200040 Beijing West Road, Shanghai, No. 1320

Applicant before: Shanghai Institute of pharmaceutical industry

Applicant before: JIANGSU CHIATAI TIANQING PHARMACEUTICAL Co.,Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140730